Baudax Bio Announces Corporate Update
October 18, 2023 08:00 ET
|
Baudax Bio
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia...
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
September 28, 2023 08:00 ET
|
Baudax Bio
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies...
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
September 07, 2023 08:00 ET
|
Baudax Bio
MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies...
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
August 23, 2023 08:00 ET
|
Baudax Bio
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies...
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 17, 2023 08:00 ET
|
Baudax Bio
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing...
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 16, 2023 08:00 ET
|
Baudax Bio
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB)...
Baudax Bio Acquires TeraImmune, Inc.
June 30, 2023 08:00 ET
|
Baudax Bio
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of...
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
June 07, 2023 09:21 ET
|
Baudax Bio
MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today...
Baudax Bio Announces Date of Reconvened Annual Meeting
June 06, 2023 09:00 ET
|
Baudax Bio
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently...